News coverage about Amyris (NASDAQ:AMRS) has been trending somewhat positive recently, according to Accern Sentiment. Accern identifies negative and positive news coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Amyris earned a media sentiment score of 0.10 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 46.4946042979229 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Here are some of the news stories that may have effected Accern Sentiment’s analysis:
- Investor Focus – Technical Watch for Amyris Inc (AMRS) – Financial … - Financial News Review (finnewsreview.com)
- Technical Watch – Amyris, Inc. (AMRS) moves -86.50% off from One Year High - Voice Of Analysts (analystsbuzz.com)
- Chart Trading: Viewing Signals For Amyris Inc (AMRS) - Hayden Business Journal (haydenbusinessjournal.com)
- Dissecting the Numbers for KAR Auction Services, Inc. (KAR) and Amyris, Inc. (AMRS) - StockNewsGazette (stocknewsgazette.com)
- Amyris, Inc. (NASDAQ:AMRS) Traded -26.8% Below Its 50 Day Average - Modern Readers (modernreaders.com)
Amyris (NASDAQ:AMRS) traded up 3.36% on Friday, reaching $2.46. The company’s stock had a trading volume of 140,172 shares. The stock’s 50 day moving average is $3.23 and its 200-day moving average is $5.40. Amyris has a 52 week low of $1.86 and a 52 week high of $18.15. The firm’s market capitalization is $92.51 million.
Amyris (NASDAQ:AMRS) last announced its earnings results on Thursday, August 10th. The biotechnology company reported ($1.41) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.06) by $0.35. The business had revenue of $25.68 million for the quarter, compared to analysts’ expectations of $23.68 million. During the same quarter in the previous year, the firm posted ($0.06) EPS. The firm’s quarterly revenue was up 167.5% on a year-over-year basis. Analysts predict that Amyris will post ($3.32) EPS for the current year.
A number of research analysts recently commented on AMRS shares. ValuEngine downgraded Amyris from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd. HC Wainwright set a $15.00 price target on Amyris and gave the company a “buy” rating in a report on Wednesday, June 7th. Zacks Investment Research downgraded Amyris from a “hold” rating to a “sell” rating in a report on Tuesday, July 11th. Finally, Cowen and Company set a $4.00 price target on Amyris and gave the company a “hold” rating in a report on Thursday, August 17th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the stock. Amyris presently has a consensus rating of “Hold” and an average target price of $25.70.
Amyris Company Profile
Amyris, Inc is an integrated industrial biotechnology company. The Company is engaged in research and development and sales of fuels and farnesene-derived products. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including cosmetics, flavors and fragrances (F&F), solvents and cleaners, polymers, lubricants, healthcare products and fuels.
Receive News & Ratings for Amyris Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
